Oncology
T-Cell Malignancies
1
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
T-cell Malignancies is an early-stage landscape with 1 program across 2 companies. The most active players are Electra Therapeutics Inc., Fundamenta Therapeutics, Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 11
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
8
clinical trials
Recruiting3 · 38%
Completed2 · 25%
Unknown status2 · 25%
Suspended1 · 13%
Clinical Trials
Trial Activity
8 trials
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Recruiting·—·Phase 1/2·NCT06316427·80 enrolled
Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies
Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT05290155·14 enrolled
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
Suspended·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT04828174·9 enrolled
Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)
Unknown status·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1·NCT05397184·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)